Decreasing Total Body Phosphorus Burden in Chronic Kidney Disease
|
|
- Shon King
- 6 years ago
- Views:
Transcription
1 Decreasing Total Body Phosphorus Burden in Chronic Kidney Disease Dennis J. Chew, DVM, DACVIM Valerie J. Parker, DVM, DACVIM, DACVN The Ohio State University, Columbus, Ohio Serum phosphorus concentration depends on dietary phosphorus intake, gastrointestinal absorption across the duodenum and jejunum, translocation into intracellular sites, skeletal absorption, and excretion of phosphorus into the urine. The kidneys play a crucial role in regulating phosphorus concentrations, with a narrow range maintained in health. Young growing animals often have higher serum phosphorus levels than adults (up to 9.0 mg/dl). The normal serum phosphorus range of many laboratories includes that of adults and growing animals, which may make it difficult to detect early increases in serum phosphorus. The typical reference range for serum phosphorus for adult dogs and cats is 2.5 to 6.0 mg/dl (0.81 to 1.94 mmol/l). RENAL SECONDARY HYPERPARATHYROIDISM Normophosphatemic and hyperphosphatemic forms of phosphorus retention occur in patients with chronic kidney disease (CKD), leading to the development of renal secondary hyperparathyroidism (2-HPTH; Figures 1 & 2). Phosphate retention and hyperphosphatemia are primarily due to impaired renal phosphate excretion. Hyperphosphatemia during progressive early CKD is transient, as normophosphatemia is quickly restored under the influence of increased secretion of parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23), which increase urinary phosphate excretion. Renal 2-HPTH is commonly documented in dogs and cats with CKD. Overall frequency of renal 2-HPTH was 76% in a recent study of dogs with CKD, encountered in 36% with International Figure 2. The role of fibroblast growth factor (FGF)-23/Klotho in early chronic kidney disease. As glomerular filtration rate (GFR) declines, increases in phosphorus burden cause an increase in FGF-23 production. Calcitriol production increases under the influence of increased parathyroid hormone (PTH), which helps to restore ionized calcium (ica) concentration. In this stage of kidney disease, a normal ionized calcium concentration with elevated PTH concentration and normal to high serum phosphorus (S-Pi) concentration may be observed. With further absolute decrease in renal tubular tissue, there is decreased Klotho expression in the kidneys and parathyroid glands, with end-organ resistance to the actions of FGF-23. Thus, FGF-23 actions to excrete phosphorus or blunt PTH synthesis become less effective. In addition, the up-regulation of 24-hydroxylase increases the degradation of any remaining calcitriol. GI = gastrointestinal. Figure 1. Deleterious effects of increasing total body phosphorus burden in CKD. PTH = parathyroid hormone PTG = parathyroid gland ica++ = ionized calcium FGF = fibroblast growth factor Pi = inorganic phosphorus Renal Interest Society (IRIS) stage 1 CKD, 50% with stage 2, 96% with stage 3, and 100% with stage 4. 1 An increasing frequency of renal 2-HPTH was similarly found in cats with CKD, 2,3 affecting 84% of cats overall (from 47% of cats with stable azotemia but without clinical signs, to 100% of cats with decompensated CKD). Hyperphosphatemia is commonly in CKD patients with 2-HPTH, but 2-HPTH can be encountered in both dogs and cats with serum phosphorus within the normal reference range. Hyperphosphatemia was noted in 18% and renal 2-HPTH in 36 % of dogs with IRIS stage 1 CKD. 1 The concept that renal 2-HPTH can precede development of hyperphosphatemia in CKD has not been well appreciated in veterinary medicine. Serum phosphorus in the upper normal reference range has recently been associated with increased PTH in dogs with CKD, 1 confirming earlier reports of this association. 4,5 Excess PTH is toxic to a variety of tissues, including the kidneys, during CKD Ohio State & IAMS Symposium Proceedings: Small Animal Renal & Urinary Health
2 The complex interactions that occur between circulating ionized calcium, inorganic phosphorus, PTH, 25(OH)-vitamin D, calcitriol (1,25(OH)2-vitamin D), FGF-23, and Klotho (circulating and tissue expression) during CKD were recently reviewed in detail. 6 Relative and absolute deficits of the most biologically active vitamin D metabolite, calcitriol, are central in the genesis of renal 2-HPTH through various underlying mechanisms. Though not traditionally emphasized until very recently, deficits of 25(OH)-vitamin D are also common in CKD and may contribute to renal 2-HPTH and other adverse systemic effects. Total body phosphorus burden and increasing concentration of circulating phosphorus play a pivotal role in the development of renal 2-HPTH and are intimately related to dynamics of calcitriol and FGF-23/Klotho (Figures 2 & 3). Less FGF-23 is required to decrease calcitriol synthesis than to promote phosphaturia, so decreases in serum calcitriol concentration occur prior to phosphaturia in very early CKD. 7 High concentrations of circulating FGF-23 (for left ventricular hypertrophy and congestive heart failure) and serum phosphorus (for vascular calcification and endothelial dysfunction) have been identified as cardiovascular risk factors in humans with advanced CKD, 8 but this has not been investigated in veterinary medicine. In CKD, the increased secretion of FGF-23 may be a protective mechanism to stabilize serum phosphorus concentration with a decreasing number of nephrons. Thus, FGF-23 increases urinary phosphate excretion, decreases gastrointestinal absorption (indirectly), decreases calcitriol synthesis through inhibition of 1-α-hydroxylase, and increases calcitriol degradation through enhanced activity of 24,25-hydroxylase. These effects allow serum phosphorus to be maintained within a normal range until CKD becomes more advanced. Higher concentrations of serum phosphorus predicted an increase in serum creatinine >25% above baseline over 12 months in 47% of cats with CKD. 9 Serum phosphorus was the only clinicopathologic variable predictive of survival in one study of CKD cats. There was an increase in risk of death of nearly 12% for each mg/dl increase in phosphorus in that study. 10 Higher phosphorus concentration was associated with a higher risk of death within 1 month in another study. 11 Even when serum phosphorus was within the reference range, cats with CKD and phosphorus concentration >4.7 but <6.8 mg/dl had a higher risk of death, compared with that in cats with CKS and phosphorus <4.7 mg/dl. 12 REDUCING TOTAL BODY PHOSPHATE BURDEN An overarching principle of initial treatment of CKD is to reduce the degree of phosphorus retention within the body. Less phosphorus retention relieves the inhibitory effect of phosphorus on renal 1 α hydroxylase activity, resulting in the increased production of endogenous calcitriol and subsequent inhibition of PTH synthesis. Less phosphorus burden also decreases circulating FGF-23 and increases ionized calcium. Measures to decrease gastrointestinal (GI) absorption of dietary phosphorus are central in decreasing total body phosphate burden. Consumption of diets with lower total phosphorus content and/or decreased phosphate bioavailability and the Figure 3. Algorithm for use of diet and phosphate binders to achieve targeted serum phosphorus control in patients with chronic kidney disease. S = serum; Pi = inorganic phosphorus. addition of intestinal phosphate binders to the diet are useful methods to decrease phosphate entry into the body. 13 Dietary phosphorus restriction alone may decrease PTH or FGF-23 or prevent their increases in early stages of CKD in cats and dogs. However, diet alone will become ineffective to control PTH or FGF-23 as CKD advances, especially as serum phosphorus concentration increases. Restoration of normophosphatemia normalized PTH in many cats with early uremia, 14,15 but was successful in only a portion of uremic dogs, many of which required calcitriol to normalize PTH. 4 Serum phosphorus in the upper reference range was associated with increased PTH in dogs with CKD in 2 studies. 1,5 Concentrations of FGF-23 were higher in cats with IRIS stage 2 CKD when serum phosphorus was >4.5 mg/dl vs. <4.5 mg/dl. Cats of the same study with IRIS stage 3 CKD had much higher concentrations of FGF-23 when serum phosphorus was >5.0 mg/dl vs. <5.0 mg/dl. 16 Feeding a renal diet to cats with IRIS Stage 2, 3, or 4 CKD that were hyperphosphatemic (>4.5, >5.0, 6.0 mg/dl by IRIS stage) resulted in lower serum phosphorus, PTH, and FGF-23. Cats with CKD classified as normophosphatemic for their IRIS stage and fed the same renal diet decreased their circulating concentration of FGF-23, despite no change in PTH or serum phosphorus Ohio State & IAMS Symposium Proceedings: Small Animal Renal & Urinary Health 41
3 RESTRICTING DIETARY PHOSPHORUS CONTENT The average pet foods from the grocery store for dogs and cats contain 5 to 6 times as much phosphorus, on a mg/100 kcal-of-intake basis, than the average phosphorus intake for humans eating a Western-type diet (50 mg/100 kcal). Some pet foods contain up to 500 mg of phosphorus/100 kcal. This makes it difficult to achieve adequate dietary phosphorus restriction during CKD when feeding nontherapeutic diets. Veterinary renal diets are designed to have a phosphorus content lower than AAFCO minimal requirements for adult maintenance (dogs, 140 mg/100 kcal; cats, 125 mg/100 kcal). Commercial renal diets for dogs provide 48 to 120 mg of phosphorus/100 kcal and for cats, 80 to 117 mg/100 kcal. Although some senior or mature diets are restricted in phosphorus or protein content, these dietary constituents in such diets vary widely on a mg/100 kcal basis. 18 Comparing the phosphorus content on an energy basis (mg/100 kcal), rather than on a dry matter basis (%), is important to allow for comparison between dry and canned diets, as well as diets of different caloric concentrations. Despite the known benefits of targeted control of phosphorus burden, intestinal phosphate binders appear to be underutilized during treatment of CKD in cats and dogs. Diets with the same phosphorus content may result in different phosphorus absorption across the intestine due to differences in bioavailability. Despite similar total dietary phosphorus intake, substantial differences in phosphorus bioavailability were demonstrated in a study of cats provided phosphorus derived mostly from poultry, meat, and fish meal (less biovavailable), compared with inorganc phosphorus derived from neutral monobasic/dibasic salts (more bioavailable). 19 Animal proteins generally provide more phosphorus than vegetable proteins; however, most of the phosphorus in commercial diets typically comes from specific phosphate-containing mineral supplements (e.g., calcium phosphate, ammonium phosphate). Phytates from vegetable sources can limit calcium and phosphorus absorption across the intestine. The dietary calcium-to-inorganic phosphorus (Ca:Pi) ratio also affects intestinal phosphorus absorption. In most adult maintenance diets, Ca:Pi is about 1:1 to 2:1, whereas a ratio as high as 3.5:1 can be found in some veterinary renal therapeutic foods. A Ca:Pi in this range could act as an inherent binder to further limit Pi absorption. For owners who prefer to feed home-cooked diets, consultation with a veterinary nutritionist is advised. When a large number of home-prepared diets designed for management of CKD in dogs and cats were analyzed, many of these recipes were found to be inadequate for meeting the nutritional and clinical needs of CKD patients. 20 Treats given to animals with CKD, including foods that may be used as palatability enhancers, should provide <10% of the animal s total daily intake to avoid unbalancing the diet. Fresh or frozen fruits and vegetables generally make good low-phosphorus treats; the amount to be fed will depend on the individual animal s size and desired caloric intake. A good resource for determining nutrient concentrations of specific people foods is the USDA Nutrient Database ( Commercial pet treats can vary tremendously in phosphorus concentration. USE OF INTESTINAL PHOSPHATE-BINDING AGENTS Despite the known benefits of targeted control of phosphorus burden, intestinal phosphate binders appear to be underutilized during treatment of CKD in cats and dogs. In a study of treatment for cats with CKD, intestinal phosphate binders were prescribed for only 22% of the cats. 21 Similar data are not available for how frequently intestinal phosphate binders are prescribed for dogs with CKD. Phosphorus binding agents are given orally to trap phosphorus in the gut and increase insoluble phosphate salt excretion into feces. Phosphate binders work because the cation in the binder combines with dietary phosphate, producing insoluble, non-absorbable phosphate compounds. Intestinal phosphate binders function best when given with meals or within 2 hours of feeding. Other drugs should be given 1 hour before or 3 hours after any intestinal phosphate binder, to limit the effect on drug absorption. The dose of any phosphate binder should be based on the meal size (phosphorus intake) and the prevailing serum phosphorus level for each CKD patient, and is titrated to effect. No phosphate binders have yet been licensed as a drug in veterinary medicine, as they have in human nephrology. 22 All phosphate binders work best when given in the food to bind phosphorus or reduce digestibility of phosphorus in the food. The ideal intestinal phosphate binder avidly binds Pi within the intestinal lumen to increase fecal excretion of dietary phosphorus. Phosphate binders can be given within a few hours of eating, but the decrease in phosphorus absorption is not as efficient. Various classes of Pi binders (Table 1) can be similarly effective in control of serum phosphorus, but may be quite different in the degree of FGF-23 control achieved. 13 Special consideration should be given in selection of class of intestinal phosphate binder when calcitriol will also be prescribed. Sevelamer interfered with absorption of orally administered calcitriol when lanthanum did not. 23 Calcium-based intestinal phosphate binders are now rarely used in human nephrology, in part because of the increased use of calcitriol or other activated vitamin D metabolites to provide vitamin D-receptor activation and concerns for development of vascular calcification. 24 All calcium salts can result in ionized hypercalcemia as an adverse effect. The use of calcium salts could have an advantage in CKD patients that remain hypocalcemic following reduction in serum phosphorus concentrations Ohio State & IAMS Symposium Proceedings: Small Animal Renal & Urinary Health
4 Table 1. Dosage for treatment with intestinal phosphate binders in CKD. All binders should be given with a meal or preferably in the meal. Unless specified otherwise, all dosages are for dogs and cats. Intestinal Phosphate Binder Aluminum Salts Aluminum hydroxide Alternagel o 600 mg/5 ml Dosage No safe dose is known in human CKD. Measure serum aluminum? Phos-Bind o 200 g container o 500 mg/scoop o Rx Vitamins for Pets ConSeal-AlH o Chewable; 200 mg/chew o Bock Vet Pharma Sucralfate o Inefficient provider of aluminum binding Calcium Salts Calcium carbonate Tums regular strength o 500 mg/tablet Measure serum calcium; ionized calcium preferred over total calcium in CKD Avoid magnesium-containing formulations Calcium acetate More Pi binding & less hypercalcemia than carbonate salt Epakitin 1 g/10 lb., twice daily with food Vetoquinol Chitosan, 10% calcium carbonate Sevelamer Salts Lanthanum carbonate Organic poymer; can bind vitamins at high doses; coagulopathy at very high doses mg/kg/day, PO, divided in food Fosrenol Shire Co 500 mg chewable tablets Emerging Binders Pronefra Calcium carbonate, magnesium carbonate Virbac Lenziaren Iron oxide with sucrose and starch Novartis Niacin Cheap and effective Not fully evaluated in dogs or cats with clinical CKD Evaluated in normal cats only Measure serum magnesium in CKD? 0.5 ml/kg/day in food Evaluated only in cats 0.50 to 1.0 g/cat/day for maintenance food 0.25 to1.0 g/cat/day for renal food Humans only 1,000 to 1,500 mg/day CKD=chronic kidney disease; Pi = inorganic phosphorus 2015 Ohio State & IAMS Symposium Proceedings: Small Animal Renal & Urinary Health 43
5 Intestinal phosphate binders should be mixed in food at appropriate doses to achieve a specific targeted serum phosphorus, PTH, or FGF-23 concentration. Optimal PTH control occurs in dogs with CKD when a targeted serum phosphorus of < 4.5 mg/dl 1,5 or when the middle of the reference range is achieved. Return of serum phosphorus to within the normal reference range is an initial goal, but does not guarantee adequate control of PTH or FGF-23 production. Serial measurement of serum phosphate concentration is important for patients with CKD managed with a renal diet and when intestinal phosphate binders are prescribed (Figure 3). Monitoring is usually monthly until the target concentration has been achieved, and then every 2 to 4 months thereafter if stable. Serum phosphorus concentration may increase in CKD patients that increase their food intake following other supportive CKD treatments. Achieving mid-reference range target phosphate concentrations is more difficult in those with more advanced levels of azotemia. Less stringent target guidelines for serum phosphorus control (<6.0 mg/dl or 1.94 mmol/l for Stage 4; <5.0 mg/dl or 1.61 mmol/l, stage 3; <4.5 mg/dl or 1.45 mmol/l, stage 2), based on IRIS stage of CKD, have been suggested. 25 Measuring ionized calcium, in conjunction with PTH, as additional targets is ideal. Adverse effects of phosphate binders can occur. Although hypophosphatemia is one such possible consequence, it is difficult to develop with initially high concentrations of serum phosphorus and reduced glomerular filtration rate. Constipation and GI effects can occur following use of some intestinal phosphate binders. Chemicals from the phosphate binder may be absorbed and accumulate in body tissues, and may produce adverse effects. Some binders also can decrease GI absorption of vitamins. REFERENCES 1. Cortadellas O, Fernandez del Palacio MJ, Talavera J, Bayon A. Calcium and phosphorus homeostasis in dogs with spontaneous chronic kidney disease at different stages of severity. J Vet Intern Med 2010;24: Elliott J, Barber PJ. Feline chronic renal failure: clinical findings in 80 cases diagnosed between 1992 and J Small Anim Pract 1998;39: Barber PJ, Elliott J. Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and J Small Anim Pract 1998;39: Nagode LA, Chew DJ. Podell M. Benefits of calcitriol therapy and serum phosphorus control in dogs and cats with chronic renal failure. Both are essential to prevent or suppress toxic hyperparathyroidism. Vet Clin North Am Small Anim Pract 1996;26: Nagode LA, Chew DJ. Nephrocalcinosis caused by hyperparathyroidism in progression of renal failure: treatment with calcitriol. Semin Vet Med Surg 1992;7: de Brito Galvao JF, Nagode LA, Schenck PA, Chew DJ. Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. J Vet Emerg Crit Care (San Antonio) 2013;23: Williams ME. Chronic kidney disease/bone and mineral metabolism: the imperfect storm. Seminars in Nephrology 2009;29: Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014;10: Chakrabarti S, Syme HM, Elliott J. Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. J Vet Intern Med 2012;26: Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M. Survival in cats with naturally occurring chronic kidney disease ( ). J Vet Intern Med 2008;22: Kuwahara Y, Ohba Y, Kitoh K, Kuwahara N, Kitagawa H. Association of laboratory data and death within one month in cats with chronic renal failure. J Small Anim Pract 2006;47: King JN, Tasker S, Gunn-Moore DA, Strehlau G. Prognostic factors in cats with chronic kidney disease. J Vet Intern Med 2007;21: Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82: Elliott J, Rawlings JM, Markwell PJ, Barber PJ. Survival of cats with naturally occurring chronic renal failure: effect of dietary management. J Small Anim Pract 2000;41: Barber PJ, Rawlings JM, Markwell PJ, Elliott J. Effect of dietary phosphate restriction on renal secondary hyperparathyroidism in the cat. J Small Anim Pract 1999;40: Geddes RF, Finch NC, Elliott J, Syme HM. Fibroblast growth factor 23 in feline chronic kidney disease. J Vet Intern Med 2013;27: Geddes RF, Elliott J, Syme HM. The effect of feeding a renal diet on plasma fibroblast growth factor 23 concentrations in cats with stable azotemic chronic kidney disease. J Vet Intern Med 2013;27: Hutchinson D, Freeman LM, Schreiner KE, Terkla DG. Survey of Opinions About Nutritional Requirements of Senior Dogs and Analysis of Nutrient Profiles of Commercially Available Diets for Senior Dogs. Intern J Appl Res Vet Med 2011;9: Finco DR, Barsanti JA, Brown SA. Influence of dietary source of phosphorus on fecal and urinary excretion of phosphorus and other minerals by male cats. Am J Vet Res 1989;50: Larsen JA, Parks EM, Heinze CR, Fascetti AJ. Evaluation of recipes for home-prepared diets for dogs and cats with chronic kidney disease. J Am Vet Med Assoc 2012;240: Markovich JE, Freeman LM, Labato MA, Heinze CR. Survey of and medication practices of owners of cats with chronic kidney disease. J Feline Med Surg Kidder AC, Chew D. Treatment options for hyperphosphatemia in feline CKD: what's out there? J Feline Med Surg 2009;11: Pierce D, Hossack S, Poole L, Robinson A, Van Heusen H, Martin P, Smyth M. The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol Dial Transplant 2011;26: Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 2011;26: Geddes RF, Finch NC, Syme HM, Elliott J. The role of phosphorus in the pathophysiology of chronic kidney disease. J Vet Emerg Crit Care (San Antonio) 2013;23: Ohio State & IAMS Symposium Proceedings: Small Animal Renal & Urinary Health
Velphoro (sucroferric oxyhydroxide)
STRENGTH DOSAGE FORM ROUTE GPID 500mg chewable tablet oral 36003 MANUFACTURER Fresenius Medical Care North America INDICATION(S) For the control of serum phosphorus levels in patients with chronic kidney
More informationThe Management of Phosphataemia in Renal Dogs or Cats
The Management of Phosphataemia in Renal Dogs or Cats improves both the quality of life and the life expectancy of animals. THE CARDIOLOGY - NEPHROLOGY DIMENSION PAIN INFLAMMATION ANTI-INFECTIVE PHOSPHATAEMIA
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers STAGED
More informationDavid Bruyette, DVM, DACVIM
VCAwestlaspecialty.com David Bruyette, DVM, DACVIM Disorders of calcium metabolism are common endocrine disorders in both dogs and cats. In this article we present a logical diagnostic approach to patients
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007 Hosted by: Australian Small Animal Veterinary Association (ASAVA) Australian Small Animal Veterinary Association (ASAVA)
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationNormal kidneys filter large amounts of organic
ORIGINAL ARTICLE - NEPHROLOGY Effect Of Lanthanum Carbonate vs Calcium Acetate As A Phosphate Binder In Stage 3-4 CKD- Treat To Goal Study K.S. Sajeev Kumar (1), M K Mohandas (1), Ramdas Pisharody (1),
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationLiterature Scan: Phosphate Binders
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFibroblast growth factor-23 in canine chronic kidney disease THESIS
Fibroblast growth factor-23 in canine chronic kidney disease THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University
More informationInnovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN
Innovations in Nutritional Therapy for Cats with CKD Rebecca Mullis, DVM, DACVN Content presented at the 2017 Hill s Global Symposium in Washington D.C., May 5-6, 2017. Chronic kidney disease (CKD) is
More informationTHE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION
THE IMPACT OF SERUM PHOSPHATE LEVELS IN CKD-MBD PROGRESSION Mario Cozzolino, MD, PhD, Fellow of the European Renal Association Department of Health Sciences University of Milan Renal Division & Laboratory
More informationClinical Guideline Bone chemistry management in adult renal patients on dialysis
Clinical Guideline Bone chemistry management in adult renal patients on dialysis This guidance covers how to: Maintain serum phosphate 0.8 to 1.7mmol/L 1 Maintain serum corrected calcium 2.1 to 2.5mmol/L
More informationPHOSPHATEMIA MANAGEMENT IN THE TREATMENT OF CHRONIC KIDNEY DISEASE A ROUNDTABLE DISSCUSSION. Sponsored by
PHOSPHATEMIA MANAGEMENT IN THE TREATMENT OF CHRONIC KIDNEY DISEASE A ROUNDTABLE DISSCUSSION Sponsored by PHOSPHATEMIA MANAGEMENT IN THE TREATMENT OF CHRONIC KIDNEY DISEASE Moderator Jonathan Elliott, MA,
More informationChronic kidney disease dietary management role in dogs
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Chronic kidney disease dietary management role in dogs Author : Helen Rooney Categories : Clinical, Practical, RVNs Date :
More informationMalnutrition and Role of Nutrition in BMD:CKD
Malnutrition and Role of Nutrition in BMD:CKD PNDS Continuing Nutrition Education Seminar Saturday, 30 th November 2013 Fayza Khan MSC (Foods and Nutrition) R.D President,PNDS Outline Objective Malnutrition
More informationBEC FEED SOLUTIONS NEW ZEALAND Ltd
BEC FEED SOLUTIONS NEW ZEALAND Ltd Proudly sponsor Dr Alessandro Mereu Yara Feed Phosphates July 2017 NZARN Meeting www.becfeed.co.nz Phosphorus metabolism in cattle: principles and interactions with Ca
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson-Zachrisson, 3
More informationNOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT Phosphate Binders for the Treatment of Hyperphosphataemia in adults with Chronic Kidney Disease OBJECTIVES To outline referral
More informationThe hart and bone in concert
The hart and bone in concert Piotr Rozentryt III Department of Cardiology, Silesian Centre for Heart Disease, Silesian Medical University, Zabrze, Poland Disclosure Research grant, speaker`s fee, travel
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationTherapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationDiagnostic Staging and Management of Dogs and Cats with Chronic Kidney Disease
Diagnostic Staging and Management of Dogs and Cats with Chronic Kidney Disease Dr Sheri J. Ross, BSc, DVM, PhD, Dipl. ACVIM (Internal Medicine) Abstract: Chronic kidney disease (CKD) is defined as primary
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationObesity Prevention & Management. Valerie J. Parker, DVM, DACVIM, DACVN
Obesity Prevention & Management Valerie J. Parker, DVM, DACVIM, DACVN The Problem Approximately 59% of dogs and cats are overweight. This is the most commonly diagnosed nutritional disorder in veterinary
More informationGrowth, Maintenance, Gestation/Lactation
SENSITIVE-GI TM Sensitive-GI TM Feline formulas contain a limited number of highly digestible ingredients and provide a nutrient profile that is known to benefit gastrointestinal health, appropriately
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationChronic kidney disease in cats
Chronic kidney disease in cats What is chronic kidney disease (CKD)? Chronic kidney disease (CKD) is the name now used to refer to cats with kidney failure (or chronic kidney failure). CKD is one of the
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationNATURAL APPROACHES TO FEEDING THE PET DOG OR CAT
NATURAL APPROACHES TO FEEDING THE PET DOG OR CAT As a modern society, we understand the importance of food quality in maintaining or improving our health. We know that we need to eat good quality food
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.04 Effective Date: 11.15.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationEfficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren in healthy cats fed a standard diet
King et al. BMC Veterinary Research 2014, 10:258 RESEARCH ARTICLE Open Access Efficacy, acceptability and tolerability of the new oral phosphate binder in healthy cats fed a standard diet Jonathan N King
More informationLunch and Learn Fresno Veterinary Specialty and Emergency Center March 19, Domenico Bianco, DVM, PhD, DACVIM
Lunch and Learn Fresno Veterinary Specialty and Emergency Center March 19, 2013 Domenico Bianco, DVM, PhD, DACVIM Outline Diagnosis of chronic kidney disease (CKD) Acute kidney injury (AKI) vs. CKD International
More informationSpecial Aspects of Diagnosing and Managing Chronic Kidney Disease Dennis Chew, DVM, DACVIM The Ohio State University Columbus, OH
Special Aspects of Diagnosing and Managing Chronic Kidney Disease Dennis Chew, DVM, DACVIM The Ohio State University Columbus, OH The incidence of the diagnosis of CKD in cats is made 2 to 3 times as frequently
More informationMajor intra and extracellular ions Lec: 1
Major intra and extracellular ions Lec: 1 The body fluids are solutions of inorganic and organic solutes. The concentration balance of the various components is maintained in order for the cell and tissue
More informationTenapanor, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia
, a gastrointestinal NHE3 inhibitor, reduces serum phosphate in patients with chronic kidney disease stage 5D and hyperphosphatemia Geoffrey A Block, 1 David P Rosenbaum, 2 Maria Leonsson- Zachrisson,
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationNon-protein nitrogenous substances (NPN)
Non-protein nitrogenous substances (NPN) A simple, inexpensive screening test a routine urinalysis is often the first test conducted if kidney problems are suspected. A small, randomly collected urine
More informationChronic Kidney Disease Mineral Bone Disease
NHS Logo here Chronic Kidney Disease Mineral Bone Disease (CKD-MBD) Patient Information Health & care information you can trust The Information Standard Certified Member Working together for better patient
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationHealthy cats 2. SENIOR CONSULT
Healthy cats 2. SENIOR CONSULT SENIOR CONSULT STAGE 1 dry SENIOR CONSULT STAGE 2 dry Healthy cats 2. SENIOR CONSULT SVG_ProductsBook_Cat.indd 11 30/05/2017 09:33 VITALITY COMPLEX OPTIMAL ENERGY kcal SENIOR
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationChronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
Nutrition and Dietetic Service Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Authors Hilary Mathieson, Renal Dietitian Paul McKeveney, Consultant Nephrologist
More informationThe Latin American Veterinary Conference TLAVC 2006 pág 8
The Latin American Veterinary Conference TLAVC 2006 pág 8 CHRONIC RENAL FAILURE David F. Senior, BVSc, Dipl. ACVIM-SA; ECVIM-CA School of Veterinary Medicine Louisiana State University, Baton Rouge, LA
More informationMonth/Year of Review: May 2014 Date of Last Review: September New Drug Evaluation: Sucrofferic Oxyhydroxide (Velphoro )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationProceeding of the NAVC North American Veterinary Conference Jan. 8-12, 2005, Orlando, Florida
Proceeding of the NAVC North American Veterinary Conference Jan. 8-12, 2005, Orlando, Florida Reprinted in the IVIS website with the permission of the NAVC http:/// P and Published in IVIS with the permission
More informationCOMMON MEDICINES USED IN CKD CHRONIC KIDNEY DISEASE
CHRONIC KIDNEY DISEASE 1 This information is intended to help you understand why you need to take your medicines. There are multiple medicines that are used to control the symptoms related to CKD. You
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationDraft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)
Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationThe Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD
The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How
More informationEffect of High Available Phosphorus Corn and Elevated Fat and Protein. Corn on Nutrient Digestibility and Excretion in Finishing Pigs
Effect of High Available Phosphorus Corn and Elevated Fat and Protein Introduction Corn on Nutrient Digestibility and Excretion in Finishing Pigs S. L. Hankins, A. L. Sutton and B. T. Richert Department
More informationEffects of Trace Mineral Source on Growth and Mineral Balance in Yearling Horses
Effects of Trace Mineral Source on Growth and Mineral Balance in Yearling Horses T.L. Naile, S.R. Cooper, D.W. Freeman, and C.R. Krehbiel Story in Brief Sixteen yearling Quarter Horses were used in a split-plot
More informationProtocol GTC : A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients.
Protocol GTC-68-208: A Randomized, Open Label, Parallel Design Study of Sevelamer Hydrochloride (Renagel ) in Chronic Kidney Disease Patients. These results are supplied for informational purposes only.
More informationLanthanum Carbonate Reduces Urine Phosphorus Excretion: Evidence of High-Capacity Phosphate Binding
Renal Failure, 34(3): 263 270, (2012) Copyright Informa Healthcare USA, Inc. ISSN 0886-022X print/1525-6049 online DOI: 10.3109/0886022X.2011.649657 Lanthanum Carbonate Reduces Urine Phosphorus Excretion:
More informationChronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol
This is an official Northern Trust policy and should not be edited in any way Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) Dietetic Management Protocol Reference Number: NHSCT/12/553 Target
More informationNew Medicines Profile. December 2013 Issue No. 13/04. Colestilan
New Medicines Profile December 2013 Issue. 13/04 Concise evaluated information to support the managed entry of new medicines in the NHS Summary (BindRen ) is an oral, non-absorbed, non-calcium, nonmetallic
More informationKlotho: renal and extra-renal effects
Klotho: renal and extra-renal effects Juan F. Navarro-González, MD, PhD, FASN Nephrology Service and Research Division University Hospital Nuestra Señora de Candalaria Santa Cruz de Tenerife. Spain Klotho:
More informationCPT David J. Licciardello, DVM Veterinary Advisor
CPT David J. Licciardello, DVM Veterinary Advisor Carbohydrates Fats (Fatty Acids) Minerals Proteins (Amino Acids) Vitamins Water Referred to as Fiber Made up of the forage portion of a diet In a complete
More informationBASICS OF NUTRITION PROTEIN
BASICS OF NUTRITION PROTEIN Protein, the type of protein, where it comes from (plant vs. protein) and its ability to be digested is very important. Proteins are comprised of approximately 20 different
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationManagement of common uroliths through diet
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Management of common uroliths through diet Author : Marge Chandler Categories : Canine, Companion animal, Feline, Vets Date
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant ( 1997) 12: 1223 1228 Original Article Nephrology Dialysis Transplantation Reduced calcium dialysate in CAPD patients: ecacy and limitations A. Armstrong1, J. Beer1, K. Noonan2
More informationHead and Neck Endocrine Surgery
Objectives Endocrine Physiology Risk factors for hypocalcemia Management strategies Passive vs. active Treatment of hypocalcemia Department of Head and Neck Management of Calcium in Thyroid and Parathyroid
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationEFFECT OF AN ALUMINUM SUPPLEMENT ON NUTRIENT DIGESTIBILITY AND MINERAL METABOLISM IN THOROUGHBRED HORSES
K.A. Roose et al. 119 EFFECT OF AN ALUMINUM SUPPLEMENT ON NUTRIENT DIGESTIBILITY AND MINERAL METABOLISM IN THOROUGHBRED HORSES K. A. ROOSE, K. E. HOEKSTRA, J. D. PAGAN, R. J. GEOR Kentucky Equine Research,
More informationThe Parathyroid Glands
The Parathyroid Glands Bởi: OpenStaxCollege The parathyroid glands are tiny, round structures usually found embedded in the posterior surface of the thyroid gland ([link]). A thick connective tissue capsule
More informationOF DIETARY CATION-ANION BALANCE ON MINERAL BALANCE IN HORSES. Story In Brief
EFFECf OF DIETARY CATION-ANION BALANCE ON MINERAL BALANCE IN HORSES L. A. Bakerl, D.R. Topliff2, D.W. Freeman2, RG. Teeter3 and I.E. Breazile4 Story In Brief Four mature sedentary geldings were used in
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationIntroduction to MUN. What is Urea
Introduction to MUN What is Urea Urea is a small organic molecule composed of carbon, nitrogen, oxygen, and hydrogen. Urea is a common constituent of blood and other body fluids. Urea is formed from ammonia
More informationDiagnosis and management of feline iatrogenic hypothyroidism
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Diagnosis and management of feline iatrogenic hypothyroidism Author : Sarah Caney Categories : Companion animal, Feline, Vets
More informationAmani Alghamdi. Slide 1
Minerals in the body Amani Alghamdi Slide 1 The Minerals Small, naturally occurring, inorganic, chemical elements Serve as structural components Minerals classification The minerals present in the body
More informationUrinary Calculus Disease. Urinary Stones: Simplified Metabolic Evaluation. Urinary Calculus Disease. Urinary Calculus Disease 2/8/2008
Urinary Stones: Simplified Metabolic Evaluation Marshall L. Stoller, M.D. Professor and Vice Chairman Department of Urology University of California San Francisco Incidence: 7-21/10,000 3 men: 1 woman
More informationOn the Menu. Sketch Chronic Kidney Disease Paradigm shift from late diagnosis and treatment to earlier detection/intervention
Chronic Kidney Disease Paradigm shift from late diagnosis and treatment to earlier detection/intervention Serge Chalhoub, DVM, Dipl. ACVIM (SAIM) On the Menu 1. Diagnosis and prediction of feline CKD in
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationHyperparathyroidism. There is however another more potent method to achieve the lowering of PTH in a more natural way.
Hyperparathyroidism Old Theory The parathyroid glands maintain proper levels of both calcium and phosphorus in your body by turning the secretion of parathyroid hormone (PTH) off or on, much like a thermostat
More informationCardiac Nutrition Healthy eating for a strong heart beating
Cardiac Nutrition Healthy eating for a strong heart beating Julia Shih VMD, DACVIM (Cardiology) Key Topics Role of Nutrition Optimal Weight Important Nutrients Restricted Nutrients Supplements The Individual
More informationFELINE THYROID DISEASE: FOCUS ON NEW APPROACHES AND TREATMENTS
Vet Times The website for the veterinary profession https://www.vettimes.co.uk FELINE THYROID DISEASE: FOCUS ON NEW APPROACHES AND TREATMENTS Author : SARAH CANEY Categories : Vets Date : August 12, 2013
More informationRenal Control of Calcium, Phosphate, and Magnesium Homeostasis
Renal Physiology Renal Control of Calcium, Phosphate, and Magnesium Homeostasis Judith Blaine, Michel Chonchol, and Moshe Levi Abstract Calcium, phosphate, and magnesium are multivalent cations that are
More informationPro: Should phosphate binders be used in chronic kidney disease stage 3 4?
Nephrol Dial Transplant (2016) 31: 184 188 doi: 10.1093/ndt/gfv405 Advance Access publication 17 December 2015 Polar Views in Nephrology Pro: Should phosphate binders be used in chronic kidney disease
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationInfants. Lecture 21: Nutrition for Infants. Infants Metabolic Rate. Age 0-1 yrs. Massive weight gain. Calorie, vitamin and mineral needs are high
Lecture 21: Nutrition for Infants Nutrition 150 Shallin Busch, Ph.D. Age 0-1 yrs Infants Massive weight gain Weight doubles by 5 months Weight triples by 12 months Calorie, vitamin and mineral needs are
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHOSLYRA safely and effectively. See full prescribing information for PHOSLYRA. PHOSLYRA (calcium
More informationRenal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology
Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics
More informationEFFECT OF DIETARY CATION-ANION DIFFERENCE ON MINERAL BALANCE IN WEANLING HORSES. Authors:
EFFECT OF DIETARY CATION-ANION DIFFERENCE ON MINERAL BALANCE IN WEANLING HORSES 1999 Animal Science Research Report Authors: Story in Brief Pages 182-188 S.R. Cooper, D.R. Topliff, D.W. Freeman, J.E. Breazile
More informationAllergies and Food Intolerances The Raw Solution
Allergies and Food Intolerances The Raw Solution Allergies are perhaps the single most frequent reason a pet might visit the vet. Itchy skin, ear infections and gastrointestinal upset are symptoms of a
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationThe Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels
17.6 The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels Partially embedded in the posterior surface of the lateral lobes of the thyroid gland
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationGROWTH/SENSITIVE-GI TM
GROWTH/SENSITIVE-GI TM Growth/Sensitive-GI TM canine dry and wet diets contain a limited number of highly digestible ingredients and provide a nutrient profile that is known to benefit gastrointestinal
More informationPediatric Nutrition and Kidney Disease
Pediatric Nutrition and Kidney Disease Loai Eid, MD, MSHS, FAAP Consultant Pediatric Nephrologist Pediatric Nephrology & Hypertension Division Chief Dubai Hospital - DHA 26 th October, 2017 Objectives
More informationUrine dilution: a key factor in the prevention of struvite and calcium oxalate uroliths
Published in IVIS with the permission of the editor Close window to return to IVIS ROYAL CANIN VIEWPOINT Urine dilution: a key factor in the prevention of struvite and calcium oxalate uroliths KEY POINTS
More information